BACKGROUND: Patients with osteoporosis who receive tooth extractions are typically on either oral bisphosphonate or parathyroid hormone (PTH) therapy. Currently, the consequence of these therapies on hard- and soft-tissue healing in the oral cavity is not clearly defined. The aim of this study is to determine the differences in the therapeutic effect on tooth-extraction wound healing between bisphosphonate and PTH therapies. METHODS: Maxillary second molars were extracted in Sprague Dawley rats (n = 30), and either bisphosphonate (zoledronate [Zol]), PTH, or saline (vehicle control [VC]) was administered for 10 days (n = 10 per group). Hard-tissue healing was evaluated by microcomputed tomography and histomorphometric analyses. Collagen, blood vessels, inflammatory cell infiltration, and cathepsin K expression were assessed in soft tissue using immunohistochemistry, quantitative polymerase chain reaction, and immunoblotting. RESULTS: Both therapies significantly increased bone fill and suppressed vertical bone loss. However, considerably more devital bone was observed in the sockets of rats on Zol versus VC. Although Zol increased the numbers of blood vessels, the total blood vessel area in soft tissue was significantly smaller than in VC. PTH therapy increased osteoblastic bone formation and suppressed osteoclasts. PTH therapy promoted soft-tissue maturation by suppressing inflammation and stimulating collagen deposition. CONCLUSION: Zoledronate therapy deters whereas PTH therapy promotes hard- and soft-tissue healing in the oral cavity, and both therapies prevent vertical bone loss.
BACKGROUND:Patients with osteoporosis who receive tooth extractions are typically on either oral bisphosphonate or parathyroid hormone (PTH) therapy. Currently, the consequence of these therapies on hard- and soft-tissue healing in the oral cavity is not clearly defined. The aim of this study is to determine the differences in the therapeutic effect on tooth-extraction wound healing between bisphosphonate and PTH therapies. METHODS: Maxillary second molars were extracted in Sprague Dawley rats (n = 30), and either bisphosphonate (zoledronate [Zol]), PTH, or saline (vehicle control [VC]) was administered for 10 days (n = 10 per group). Hard-tissue healing was evaluated by microcomputed tomography and histomorphometric analyses. Collagen, blood vessels, inflammatory cell infiltration, and cathepsin K expression were assessed in soft tissue using immunohistochemistry, quantitative polymerase chain reaction, and immunoblotting. RESULTS: Both therapies significantly increased bone fill and suppressed vertical bone loss. However, considerably more devital bone was observed in the sockets of rats on Zol versus VC. Although Zol increased the numbers of blood vessels, the total blood vessel area in soft tissue was significantly smaller than in VC. PTH therapy increased osteoblastic bone formation and suppressed osteoclasts. PTH therapy promoted soft-tissue maturation by suppressing inflammation and stimulating collagen deposition. CONCLUSION:Zoledronate therapy deters whereas PTH therapy promotes hard- and soft-tissue healing in the oral cavity, and both therapies prevent vertical bone loss.
Authors: Valentina Guarneri; David Miles; Nicholas Robert; Véronique Diéras; John Glaspy; Ian Smith; Christoph Thomssen; Laura Biganzoli; Tanya Taran; PierFranco Conte Journal: Breast Cancer Res Treat Date: 2010-04-02 Impact factor: 4.872
Authors: Per Aspenberg; Harry K Genant; Torsten Johansson; Antonio J Nino; Kyoungah See; Kelly Krohn; Pedro A García-Hernández; Christopher P Recknor; Thomas A Einhorn; Gail P Dalsky; Bruce H Mitlak; Anke Fierlinger; Mark C Lakshmanan Journal: J Bone Miner Res Date: 2010-02 Impact factor: 6.741
Authors: Jeanny B Aragon-Ching; Yang-Min Ning; Clara C Chen; Lea Latham; Jean-Pierre Guadagnini; James L Gulley; Philip M Arlen; John J Wright; Howard Parnes; William D Figg; William L Dahut Journal: Cancer Invest Date: 2009-02 Impact factor: 2.176
Authors: Roland D Chapurlat; Monique Arlot; Brigitte Burt-Pichat; Pascale Chavassieux; Jean Paul Roux; Nathalie Portero-Muzy; Pierre D Delmas Journal: J Bone Miner Res Date: 2007-10 Impact factor: 6.741
Authors: Hong Liu; Jian Guo; Lin Wang; Ning Chen; Andrew Karaplis; David Goltzman; Dengshun Miao Journal: J Endocrinol Date: 2009-08-27 Impact factor: 4.286
Authors: Bruce A Dye; Sylvia Tan; Vincent Smith; Brenda G Lewis; Laurie K Barker; Gina Thornton-Evans; Paul I Eke; Eugenio D Beltrán-Aguilar; Alice M Horowitz; Chien-Hsun Li Journal: Vital Health Stat 11 Date: 2007-04
Authors: Junro Yamashita; Nabanita S Datta; Yong-Hee P Chun; Dong-Ye Yang; Allison A Carey; Jaclynn M Kreider; Steven A Goldstein; Laurie K McCauley Journal: J Bone Miner Res Date: 2008-05 Impact factor: 6.741
Authors: Megan N Michalski; Anna L Seydel; Erica M Siismets; Laura E Zweifler; Amy J Koh; Benjamin P Sinder; J Ignacio Aguirre; Kamran Atabai; Hernan Roca; Laurie K McCauley Journal: FASEB J Date: 2018-02-22 Impact factor: 5.191